A Phase 4 interventional study of Hormone replacement therapy and Placebo in Pituitary Adenoma and Pituitary Neuroendocrine Tumor, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by Beijing Tiantan Hospital · Phase 4, Interventional, and Prevention
Among 30 studies in Pituitary Neoplasms with a site in China — 8 open to participants now, 11 under way, none of them phase 3. Pituitary Neoplasms · China.
Among the 30 studies in Pituitary Neoplasms with a site in China, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 26th registered.
200 studies on the registry are indexed under Pituitary Neoplasms; 51 are open to participants now.
Browse Pituitary Neoplasms studies →8 of the 30 studies in Pituitary Neoplasms with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18–80
The First Affiliated Hospital of Xiamen University · Sites in China
Affiliated Hospital of Nantong University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 36 Pituitary Neoplasms studies recruiting now, 14 (39%) set no upper age limit and 10 (28%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 882 is above the median of 60 across 121 interventional studies indexed under Pituitary Neoplasms.
Median enrollment 112 across the 15 interventional studies, 200 across the 15 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 30 have an industry lead sponsor. The 10 most frequent:
Beijing Tiantan Hospital is the lead sponsor of 489 studies on the registry; 293 are open to participants now.
Beijing Tiantan Hospital has 4 studies filed under Pituitary Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Pituitary Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07316101West China HospitalClinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery | 2026-12-31 |
Among the 30 studies in Pituitary Neoplasms with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Hormone replacement therapy
Drug: Placebo
Perioperative Hydrocortisone Reduction Therapy
Perioperative placebo Reduction Therapy
The incidence of adrenal insufficiency on the first or second day after surgery
Time frame: the first or second day after surgery
The incidence of adrenal insufficiency within 90 days after surgery
Time frame: Within 90 days after surgery
Plan to share: Undecided — Research data involves subject privacy
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.